Targeted polypharmacology: Discovery of dual inhibitors of tyrosine and phosphoinositide kinases
暂无分享,去创建一个
K. Shokat | Z. Knight | Beth Apsel | Jimmy A. Blair | B. González | T. Nazif | M. Feldman | B. Aizenstein | Randy Hoffman | Roger L. Williams | R. Hoffman
[1] J. Stephenson,et al. A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia , 1982, Nature.
[2] A. Bridges,et al. A synthetic inhibitor of the mitogen-activated protein kinase cascade. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[3] M. Santoro,et al. Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line. , 1995, Biochemical and biophysical research communications.
[4] M. Santoro,et al. Point Mutation of the RetProto-oncogene in the TT Human Medullary Thyroid Carcinoma Cell Line , 1995 .
[5] J. Hanke,et al. Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor , 1996, The Journal of Biological Chemistry.
[6] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[7] W. Denny,et al. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[8] H. Kwan,et al. Involvement of vascular endothelial growth factor (VEGF) in Leydig cell-macrophage interaction of the rat testes , 1998 .
[9] A. Merlo,et al. Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines. , 1999, Brain pathology.
[10] Christian Ried,et al. Structural insights into phosphoinositide 3-kinase catalysis and signalling , 1999, Nature.
[11] J. Kuriyan,et al. Crystal structure of Hck in complex with a Src family-selective tyrosine kinase inhibitor. , 1999, Molecular cell.
[12] Anthony C. Bishop,et al. Structural basis for selective inhibition of Src family kinases by PP1. , 1999, Chemistry & biology.
[13] P. Seeburg,et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. , 2000, Science.
[14] Roger L. Williams,et al. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. , 2000, Molecular cell.
[15] P. N. Rao,et al. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.
[16] G. Koehl,et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor , 2002, Nature Medicine.
[17] J. Kuriyan,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. , 2002, Cancer cell.
[18] Chao Zhang,et al. Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach. , 2003, Cancer research.
[19] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[20] D. Neuberg,et al. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[21] Michael S. Cohen,et al. Structural Bioinformatics-Based Design of Selective, Irreversible Kinase Inhibitors , 2005, Science.
[22] Carlo Rago,et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. , 2005, Cancer cell.
[23] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[24] D. Ferris,et al. Wortmannin, a widely used phosphoinositide 3-kinase inhibitor, also potently inhibits mammalian polo-like kinase. , 2005, Chemistry & biology.
[25] D. Guertin,et al. Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.
[26] Daniela S Krause,et al. Tyrosine kinases as targets for cancer therapy. , 2005, The New England journal of medicine.
[27] M. Berger,et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. , 2005, Journal of the National Cancer Institute.
[28] Philip E. Bourne,et al. Structural Evolution of the Protein Kinase–Like Superfamily , 2005, PLoS Comput. Biol..
[29] Kevan M Shokat,et al. Features of selective kinase inhibitors. , 2005, Chemistry & biology.
[30] M. Santoro,et al. BAY 43-9006 inhibition of oncogenic RET mutants. , 2006, Journal of the National Cancer Institute.
[31] Robbie Loewith,et al. A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin Signaling , 2006, Cell.
[32] John P. Overington,et al. Can we rationally design promiscuous drugs? , 2006, Current opinion in structural biology.
[33] L. Cantley,et al. Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.
[34] J. Sebolt-Leopold,et al. Mechanisms of drug inhibition of signalling molecules , 2006, Nature.
[35] T. Cloughesy,et al. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. , 2006, Cancer research.
[36] N. Gray,et al. Rational design of inhibitors that bind to inactive kinase conformations , 2006, Nature chemical biology.
[37] P. Mayinger. Faculty Opinions recommendation of A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. , 2006 .
[38] William A Weiss,et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. , 2006, Cancer cell.
[39] K. Shokat,et al. Chemically targeting the PI3K family. , 2007, Biochemical Society transactions.
[40] Joon-Oh Park,et al. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.
[41] K. Shokat,et al. Escape from HER family tyrosine kinase inhibitor therapy by the kinase inactive HER3 , 2007, Nature.
[42] Keith L. Ligon,et al. Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies , 2007, Science.
[43] C. Sawyers,et al. Cancer: Mixing cocktails , 2007, Nature.
[44] K. Shokat,et al. A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. , 2007, Cancer research.
[45] P. Furet,et al. Imidazo[4,5-c]quinolines as inhibitors of the PI3K/PKB-pathway. , 2008, Bioorganic & medicinal chemistry letters.
[46] Daniela Gabriel,et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.
[47] Holger Gerhardt,et al. Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration , 2008, Nature.
[48] Andrea B Troxel,et al. Phase II trial of sorafenib in advanced thyroid cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[50] Y. Samuels,et al. Oncogenic mutations of PIK3CA in human cancers. , 2004, Current topics in microbiology and immunology.